Real-World Outcomes and Treatments Patterns of Metastatic Castration-Resistant Prostate Cancer Patients: An Italian Retrospective Study
Author(s)
Danesi V1, Roncadori A2, Massa I1, Balzi W1, Maltoni R1, Farolfi A3
1Istituto Romagnolo per lo Studio dei tumori "Dino Amadori" IRST-IRCCS, Meldola, FC, Italy, 2Istituto Romagnolo per lo Studio dei tumori "Dino Amadori" IRST-IRCCS, Bologna, BO, Italy, 3Istituto Romagnolo per lo Studio dei tumori "Dino Amadori" IRST-IRCCS, Meldola, BO, Italy
OBJECTIVES:
This retrospective observational study assessed the real-world treatment pattern and outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients in an Italian Cancer centre (IRST).METHODS:
Adults with diagnosis of mCRPC receiving abiraterone, enzalutamide or docetaxel associated with luteinizing hormone-releasing hormone analogues as first line (1L) between 2014 and 2018 were selected from the electronic record (EHR) of IRST (Italy). Patient characteristics and treatment patterns were assessed. Overall survival (OS) and progression-free survival (PFS) from 1L were calculated using the Kaplan-Meier method. A multivariable Cox-PH model was used for analysing mortality risk factors.RESULTS:
Among 185 patients, median age was 75.1 years (range:70-80). Bone metastasis was the most frequent metastasis site (73.5%) followed by lymph-nodes (53.5%) and visceral organs (11.9%). The mean (SD) CCI score was 9.66 (1.46), ranging from 6 to 16. Abiraterone was the most frequent 1L regimen (41.1%), followed by enzalutamide (36.2%) and docetaxel (17.8%). Among patients who received a 2L treatment (N=93, 50.27%), 45.16% received docetaxel. For those patients (N=55, 29.73%) who passed into 3L, 40% received cabazitaxel. The 1L PFS were significantly longer in patients undergoing 1L hormone therapy (median PFS: Hormone therapy (HT) 21 months; Chemotherapy (CTX) 10 months; log-rank test’ p<0.0001). The median OS was 24 and 35 months for CTX and HT groups respectively (HR=0.593; 95%CI 0.393 – 0.893; p=0.0124). The presence of bone metastases (p=0.029), peripheral vascular diseases (p=0.008) and chronic kidney disease (p=0.038) were identified as risk factors for reduced overall survival. 1L hormone therapy was confirmed to be associated with lower mortality risk if compared with chemotherapy (p=0.011).CONCLUSIONS:
This study provides a more comprehensive picture of real world population documenting treatment pattern and survival outcomes of mCRPC, which were in line with those reported in literature.Conference/Value in Health Info
2022-11, ISPOR Europe 2022, Vienna, Austria
Value in Health, Volume 25, Issue 12S (December 2022)
Code
CO164
Topic
Clinical Outcomes, Methodological & Statistical Research, Study Approaches
Topic Subcategory
Clinical Outcomes Assessment, Electronic Medical & Health Records
Disease
No Additional Disease & Conditions/Specialized Treatment Areas